• Enrique Martín Mojarro, Víctor Gil, Pere Llorens, Jesús Álvarez, Silvia Flores Quesada, Osvaldo J Troiano Ungerer, Aitor Alquézar-Arbé, Javier Jacob, Pablo Herrero-Puente, Begoña Espinosa, Carolina Sánchez, Lluis Llauger, Josep Tost, Leticia Serrano, Aitor Dávila, Torres GarateRaquelRServicio de Urgencias, Hospital Severo Ochoa, Madrid, España., María Luisa López-Grima, Francisco Javier Lucas-Imbernón, Héctor Alonso, Fran Pagán, José Manuel Garrido, Òscar Miró, and Grupo de investigación ICA-SEMES.
• Servicio de Urgencias, Hospital Sant Pau i Santa Tecla, Tarragona, España.
• Emergencias. 2023 Dec 1; 35 (6): 437446437-446.

ObjectivesTo analyze factors related to the use of digoxin to treat patients with acute heart failure (AHF) in emergency departments (EDs) and the impact of digoxin treatment on short-term outcomes.Material And MethodsWe included patients diagnosed with AHF in 45 Spanish EDs. The patients, who were not undergoing long-term treatment for heart failure, were classified according to whether or not they were given intravenous digoxin in the ED. Fifty-one patient or cardiac decompensation episode variables were recorded to profile ED patients treated with digoxin. Outcome variables studied were the need for hospital admission, prolonged stay in the ED (> 24 hours) for discharged patients, prolonged hospitalization (> 7 days) for admitted patients, and all-cause in-hospital or 30-day mortality. The associations between digoxin treatment and the outcomes were studied with odds ratios (ORs) adjusted for patient and AHF episode characteristics.ResultsData for 15 549 patients (median age, 83 years; 55% women) were analyzed; 1430 (9.2%) were treated with digoxin. Digoxin was used more often in women, young patients, and those with better New York Heart Association (NYHA) classifications but more severe cardiac decompensation, especially if the trigger was atrial fibrillation with rapid ventricular response. Admissions were ordered for 75.4% of the patients overall (81.6% of digoxin-treated patients vs 74.8% of nontreated patients; P .001). The ED stay was prolonged in 38.3% of patients discharged from the ED (52.9% of digoxin-treated patients vs 37.2% of nontreated patients; P .001). The duration of hospital stay was prolonged in 48.1% (digoxin-treated, 49.3% vs 47.9%; P = .385). In-hospital mortality was 7.2% overall (6.9% vs 7.2%, P= .712), and 30-day mortality was 9.7% (9.3% vs 9.7%, P = .625). ED use of digoxin was associated with a prolonged stay in the department (adjusted OR, 1.883; 95% CI, 1.359-2.608) but not with hospitalization or mortality.ConclusionDigoxin continues to be used in one out of ten ED patients who are not already on long-term treatment with the drug. Digoxin use is associated with cardiac decompensation triggered by atrial fibrillation with rapid ventricular response, younger age, women, and patients with better initial NYHA function status but possibly more severe decompensation. Digoxin use leads to a longer ED stay but is safe, as it is not associated with need for admission, prolonged hospitalization, or short-term mortality.

22 keywords...

hide…